Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2006

View Archived Issues

BYK-191023: new selective iNOS inhibitor and candidate for inflammatory hypotension

Meta-analysis indicates beneficial effects of Chinese herbal medicine for NSCLC

Recent patents describe novel analgesic agents

A new role for Cdk5 in pain signaling

Enrollment ahead of schedule in Onconase phase IIIb study

AVI signs HCV license agreement with Chiron

Daiichi reports new agents for treating allergic disorders

Novel ophthalmic compounds described by Alcon in a recent patent

Recent patents disclose novel agents for cardiovascular disorders

PKC-412 and AMN-107 show promise in systemic mastocytosis with mutated KIT

MediGene and Bradley sign agreement for Polyphenon E Ointment

Pharmion and MethylGene sign agreement for oncology oral HDAC inhibitors

Synergistic activity seen with FK-228 and bortezomib in leukemic cells

AOD-9604 shows potential for osteoporosis

Ferring and Astellas sign licensing agreement for degarelix in Japan

BTG acquires rights to Asterand's pain compounds

Orphan drug designation for TheraQuest's high-concentration capsaicin

Benitec delays IND filing for HIV/AIDS therapeutic

SNS-032 begins phase I study in advanced solid tumor cancers

Phase II trial planned for Cloretazine in elderly poor-risk AML patients

Locus and Lilly enter research agreement

FDA accepts IND for OxyQD

Enrollment completed in phase II stress urinary incontinence study of cizolirtine

U.S. launch for Avandaryl

Amitiza approved for chronic idiopathic constipation

GlaxoSmithKline's Arranon launched for the first time in the U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...